Skip to content

H.R. 3160 · 118th Congress (2023–2025)

Pharmaceutical Research Transparency Act of 2023

This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development.

Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion.

The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.

Show official title

To amend the Public Health Service Act to increase the transparency of pharmaceutical research costs, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 3160’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Jamie Raskin (D-MD-8)
Cosponsors
1 cosponsor

0 original · 1 later

  1. Rep. Elissa Slotkin (D-MI-7)· Later · Jun 12, 2023
Policy area
Health
Subjects
  • Administrative law and regulatory procedures
  • Department of Health and Human Services
  • Government information and archives
  • Manufacturing
  • Medical research
  • Prescription drugs
  • Research and development

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · May 9, 2023 – May 12, 2023
    1. Referred to committee

      Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseFinancial ServicesReferred May 9, 2023
  2. HouseEnergy and CommerceReferred May 9, 2023
  3. HouseHealthReferred May 12, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Pharmaceutical Research Transparency Act of 2023

    Display title, Short title · Introduced in House

  2. To amend the Public Health Service Act to increase the transparency of pharmaceutical research costs, and for other purposes.

    Official title · Introduced in House